Clinical Study

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing 3 Mg And 12 Mg Of Ly3202626 With Placebo Over 52 Weeks In Approximately 500 Patients With Mild Alzheimer’S Disease Dementia.

Posted Date: Dec 2, 2016

  • Investigator: Lawrence Goldstick
  • Co-Investigator: Kayla Stallworth
  • Specialties:
  • Type of Study: Drug

This study is being done to see how safe a new investigational drug is and how well it might work to help people with Alzheimer’s disease. “Investigational” means that the drug being tested has not been approved for sale or routine clinical use in the U

Criteria:

You Cannot Be In This Study If: ? You Have Certain Neurologic Diseases Or Psychiatric Disorders. ? You Have Had Cancer In The Past 5 Years. ? You Are Not Able To Have A Magnetic Resonance Imaging (Mri) Scan. ? You Are Taking Or Have Taken Certain Medi

Keywords:

Dementia, Eli Lilly, Alzheimer’S Disease, Ly3202626, Null

For More Information:

Samantha Maldonado
(937) 535-5012
samantha.maldonado@uchealth.com

  • Search Clinical Studies

  • Research in the News

    NIDA Director Nora Volkow to Speak on Opioid Crisis Nov. 27

    Nora Volkow, MD, director of the National Institute on Drug Abuse (NIDA), willbe the keynote speaker at a public symposium on tackling the opioid crisis onMonday, Nov. 27